Golf is a unique sport. Unlike most others, it’s not primarily about beating the other players – it’s about beating the course. You are essentially playing against the environment, as the course's layout, natural obstacles, and weather conditions allHigh Dividend Opportunities, #1 On Seeking AlphaSave yourself thousands of dollars by creating a portfolio that pays you to hold it. No selling required to fund your retirement dreams. Tired of going it alone or visiting a financial advisor who just doesn't seem ...

My handle is the Michigan Value Investor, but everyone calls me MVI. I have a PhD in theoretical physics from UC Berkeley and worked briefly in the field before switching my interests to investing. I worked as an analyst at a billion dollar fund for several years before starting my own very small fund in 2009. During this time I have developed a group of stocks that I understand well, and I have excellent relations with management in many cases. This long standing familiarity with a select group of companie ...

业绩总结 - Harrow Health在2021年上半年收入达到106,966千美元，毛利率为75.6%[17] - Harrow Health预计未来几年收入将超过1亿美元，并通过收购高价值产品加速增长[21] 用户数据 - Harrow Health在2020年和2021年期间的净推荐值(NPS)在80到90之间，显示出客户满意度高[9] 新产品和新技术研发 - Harrow Health预计在2021年第四季度提交AMP-100的新药申请(NDA)，并计划在2022年晚些时候商业推出[5] - Harrow Health的AMP-100药物候选者在临床和前临床研究中显示出安全性，主要副作用为瞳孔扩张[11] 市场扩张 - Harrow Health的眼科手术和慢性眼病市场庞大，干眼症患者超过1600万，年眼科手术超过800万[8] 资金和财务策略 - Harrow Health在2021年第二季度通过发行高级无担保票据筹集了8500万美元，增强了现金流[21] 其他新策略 - Harrow Health在临床阶段和商业制药公司中持有大量股权，并在四个资助的药物开发项目中拥有特许权[22] - Harrow Health的药物候选者特许权在Surface Ophthalmics和Melt Pharmaceuticals的临床开发中分别为4%和5%[19]

业绩总结 - Harrow在2021年第三季度的收入为$18,700,000，调整后的EBITDA为$4,900,000[22] - Harrow的总资产在2021年第三季度达到了$102,801,000，毛利率为75.0%[20] 用户数据 - Harrow的ImprimisRx业务每月服务超过1,500个账户，覆盖超过10,000名开处方的医生和机构[9] - Harrow的眼科手术和慢性眼病市场庞大，干眼症患者超过1600万，年均眼科手术超过800万[8] 未来展望 - Harrow预计未来几年收入将超过$100,000,000，并通过收购高价值产品加速增长[25] - Harrow的药物候选产品AMP-100预计将在2021年第四季度向FDA提交新药申请[12] 新产品和新技术研发 - Harrow拥有Surface Ophthalmics和Melt Pharmaceuticals的药物候选权，年市场规模在数十亿美元[23] - Harrow的MAQ-100在美国的年维特切手术预计为400,000例[15] 融资活动 - Harrow在2021年第二季度通过发行高级无担保票据筹集了$85,000,000[25]

Harrow (HROW) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Jamie Webb - Director of Communications & Investor RelationsMark Baum - Chief Executive Officer and Chairman of the BoardAndrew Boll - Chief Financial OfficerJeffrey Cohen - MD - Equity ResearchYi Chen - Managing Director, Equity ResearchMayank Mamtani - Senior Managing Director Conference Call Participants Thomas Flaten - Senior Research AnalystChase Knickerbocker - Senior Equity Research Analyst - Healthcare Operator Good mo ...

Harrow (HROW) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Jamie Webb - Director of Communications & Investor RelationsMark Baum - Chief Executive Officer and Chairman of the BoardAndrew Boll - Chief Financial OfficerJeffrey Cohen - MD - Equity ResearchYi Chen - Managing Director, Equity ResearchMayank Mamtani - Senior Managing Director Conference Call Participants Thomas Flaten - Senior Research AnalystChase Knickerbocker - Senior Equity Research Analyst - Healthcare Operator Good mo ...

Harrow (HROW) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Good morning, and welcome to Harrow's First Quarter twenty twenty five Earnings Conference Call. My name is Shannon, and I will be your operator for today's call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. As a reminder, this conference is being recorded. I would now like to turn the call over to Jamie Webb, Director of Communications and Investor Relations for Harrow. S ...

Harrow (HROW) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2,000%. A quarter ago, it was expected that this pharmaceutical and drug compounding company would post earnings of $0.11 per share when it actually produced earnings of $0.25, delivering a surprise of 127.27%.Over the last four quarters, t ...

业绩总结 - 预计2025年收入超过2.8亿美元[7] - 2025年第一季度收入为47,813千美元[10] - 调整后EBITDA在2025年预计达到199,614千美元[10] - ImprimisRx在2024年第一季度的收入为83,499千美元[26] 用户数据 - IHEEZO自2023年5月推出以来，2025年第一季度客户单位需求达到49,130[14] - VEVYE自2024年1月推出以来，2025年第一季度处方量为75,409[17] 新产品和新技术研发 - TRIESENCE于2024年10月重新推出，成为强受欢迎的产品[8] - MELT-300的积极三期临床结果支持2027年第一季度的FDA批准产品推出[8] - MELT-300的NDA预计在2026年上半年提交[31] 社会责任 - Harrow的捐赠帮助了2024年约17,000名患者，2025年已承诺帮助近5,000名患者[41] 股权和市场扩张 - Harrow在Melt Pharmaceuticals的持股比例为46%[8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2025 Washington, D.C. 20549 or FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-35814 Harrow, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or other ju ...